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Edited by Ned ManteiAbstract The eﬀects of muscle splice variants of insulin-like
growth factor I (IGF-I) on proliferation and diﬀerentiation were
studied in human primary muscle cell cultures from healthy sub-
jects as well as from muscular dystrophy and ALS patients.
Although the initial numbers of mononucleated progenitor cells
expressing desmin were lower in diseased muscle, the E domain
peptide of IGF-IEc (MGF) signiﬁcantly increased the numbers
of progenitor cells in healthy and diseased muscle. IGF-I signif-
icantly enhances myogenic diﬀerentiation whereas MGF E pep-
tide blocks this pathway, resulting in an increased progenitor
(stem) cell pool and thus potentially facilitating repair and main-
tenance of this postmitotic tissue.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Muscle satellite cells were one of the ﬁrst tissue stem cells to
be identiﬁed and studied [1]. These cells are particularly impor-
tant in a postmitotic tissue such as muscle, as they are the
source of extra nuclei required for growth, repair and hyper-
trophy. Previous work [2,3] has shown that when muscle is
mechanically challenged, the IGF-I gene is initially spliced to-
wards IGF-IEc (mechano growth factor) during the period
that muscle stem cell activation occurs. Mechano growth fac-
tor (MGF) has a unique E domain resulting from a 48 bp in-
sert during the splicing of exons 5 and 6. Following this
activation period, the IGF-I gene is spliced towards IGF-
IEa, the main supply of anabolic agent in the form of mature
IGF-I, which contains the domain responsible for binding to
the IGF-I receptor [4,5]. Only recently has the lineage and sig-
nalling associated with activation processes in progenitor cells
been studied in adult human muscle [6,7]. Residual mononu-*Corresponding author. Fax: +44 20 7915 1238.
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are believed to be the main source of muscle satellite (stem)
cells that have not fused to form myotubes. However, myo-
blast is a generic term for any cell that gives rise to muscle,
and in primary cell cultures not all mononucleated cells are
progenitor cells. To determine the numbers of cells in the pro-
genitor stage there is a need for markers such as desmin [6], for
which a good antibody is available that can be used together
with the nuclear stain DAPI (Fig. 1). Hence the eﬀect of diﬀer-
ent domains of insulin-like growth factor peptides on the pro-
portion of muscle cells in the progenitor phase could be
determined (the muscle precursor pool).
Previous studies have almost invariably involved the use of
muscle cell lines and commercially available recombinant
IGF-I, which is essentially the domain encoded by exons 3
and 4 and is responsible for binding to the IGF-I receptor.
A study on bronchial epithelial cells suggested that the E pep-
tide of rodent IGF-IEb acts as an independent growth factor
[8]. In addition, data that only became publicly available just
prior to the submission of this work have indicated that
MGF E domain enhances migration of normal human primary
muscle precursor cells [9]. Here the eﬀect of the E domain of
mechano growth factor (MGF or IGF-IEc in human) on pri-
mary cultures of normal, dystrophic and ALS muscle was
studied and compared with rIGF-I and also with MGF E do-
main combined with rIGF-I. It has been known for some time
that mature IGF-I stimulates both proliferation and diﬀerenti-
ation [10], but this does not explain how the muscle progenitor
cell pool is replenished. Although transformed muscle cells
have been used previously [11], these immortalised cell lines
have apparently become somewhat depleted of progenitor cells
and require further selective cloning [12]. Therefore, it was
important to use the creatine kinase assay [13] on human pri-
mary muscle cultures to assess the level of myogenic diﬀerenti-
ation following treatment with IGF-I containing the domain
responsible for receptor binding and with the E domain of
the MGF.2. Materials and methods
2.1. Human muscle-derived cells
Human primary muscle cell cultures were isolated as previously de-
scribed [6]. With informed consent, craniofacial (masseter) muscle
biopsies were obtained from healthy adult and congenital muscularblished by Elsevier B.V. All rights reserved.
Fig. 1. Human muscle-derived cells imaged by epi-ﬂuorescent microscopy. Top: Single cell cultures immunostained for desmin and DAPI for DNA/
nuclei. Bottom: The combined staining for desmin and nuclei that was used to determine the percentage of desmin positive cells in primary human
muscle cultures.
2728 K. Ates et al. / FEBS Letters 581 (2007) 2727–2732dystrophy (CMD) patients during elective surgery at the Eastman
and Middlesex Hospitals, London, UK. Human lower limb (vastus
lateralis) muscle samples were obtained from consenting, adult
healthy, fascio-scapulo-humeral dystrophy (FSHD) and motor neu-
rone disease (ALS) patients by needle biopsy under local anaesthesia
at the Royal Free Hospital, London, UK. Muscle samples were dis-
sociated by mincing, and then tissue fragments were plated into 0.2%
gelatin coated tissue culture ﬂasks to establish explant cultures. Ex-
plants were maintained in standard growth medium (GM) that con-
tained 20% fetal calf serum (FCS, PAA) with 1% penicillin
(100 g ml1) and streptomycin (5000 g ml1) and 79% Dulbecco’s
modiﬁed Eagle’s medium (DMEM), as mononuclear cells migrated
from the explants. These cells were collected and stored under cryo-
genic conditions until they were used in the experiments described be-
low. Cells were kept below passage 10 (our previous data indicated
that the myogenic fraction remains constant up to this passage and
then declines with subsequent passage). At least six runs were per-
formed for each treatment in all of the diseased muscle cultures as
well as for the two types of healthy muscle. The commercial source
of cells was human skeletal muscle myoblasts (HSMM, Lonza
(UK)), grown and passaged as subconﬂuent monolayers. The cells
were maintained in specialised media, skeletal muscle cell basal media
(SKGM2, Lonza, UK) supplemented with 10% fetal bovine serum,
hEGF, L-glutamine, dexamethasone and gentamycin as supplied by
the company.2.2. Determination of the myogenic progenitor (stem) cell population
in vitro
All of the mononuclear cells from primary tissue used in these exper-
iments were derived from muscle explants as above. Not all of this
population contains myogenic cells. Therefore, the number of myo-
genic progenitors was determined as described previously [6]. Brieﬂy,
cells were plated on gelatin-coated (0.2%) 13 mm coverslips at an initialdensity of 4.5 · 103 cells cm2 [14]. After allowing 24 h for adherence,
MGF E domain (10 ng/ml) with and without rIGF-I (10 ng/ml) also
with and without monoclonal IGF-I receptor antibody (Ab-1,
100 lg/ml, Oncogene) was added in GM as appropriate. Peptides used
were the 24 aa E domain of MGF/IGF-IEc peptide synthesized as de-
scribed previously [15] and human 70 aa IGF-I peptide (Sigma–Al-
drich ER2 IGF-I). All media were replaced every 2–3 days. The
cultures were sampled at various time-points for immunocytochemical
analyses. Note: HSMM are supplied as at least 60% desmin positive
cells (manufacturer’s ﬁgures).2.3. Immunocytochemistry
At appropriate time points, cells were ﬁxed with methanol for 10
min (20 C), followed by detergent permeabilization with 0.5% Tri-
ton X-100 for 10–15 min. Cells were then incubated for 60 min with
an anti-desmin (1:100; clone D33, DAKO, Glostrup, Denmark) anti-
body, diluted in antibody diluting solution (ADS; PBS plus 10% FCS,
0.025% sodium azide, 0.1 M lysine). A class speciﬁc anti-mouse IgG
antibody conjugated to FITC (1:200; Jackson ImmunoResearch Lab-
oratories/Stratech Scientiﬁc) was used to visualize. Nuclei were iden-
tiﬁed by introducing the ﬂuorescent minor-groove DNA-binding
probe, DAPI (1.0 ng/ml; Sigma–Aldrich), into the ﬁnal antibody incu-
bation step. Coverslips were mounted with the glycerol-based anti-
fade agent, Citiﬂuor (Citiﬂuor Ltd). Cell-associated ﬂuorescence and
morphology [14] were visualized by epi-ﬂuorescence and Leica modu-
lation contrast (LMC) microscopy, respectively, using an inverted
Leica DMIRB microscope equipped with Leica FW4000 image pro-
cessing software (Fig. 1). All blue and green ﬂuorescent positive cells
were counted in a ﬁeld. At least 30 ﬁelds in each coverslip were
counted in a systematic manner; at least 100 cells were therefore
counted on each coverslip. The number of cells was compared as
the proportion of desmin positive cells to the total number of DAPI
positive cells.
Fig. 2. (A) The eﬀect of IGF-I isoforms on the desmin-positive fraction (myogenic precursor (stem) cells) of cells derived from normal craniofacial
(CF) and limb muscle (Limb) and primary cultures from adult patients with muscular dystrophies (CMD, FSHD) or ALS. (B) Control showing the
proliferation of commercially available human primary culture myogenic cells in response to MGF and IGF-I. Data shown are the means ± S.D.
pooled from at least four experiments. Empty bars are human muscle cells cultures treated with growth medium (GM) alone, light grey bars are
cultures treated with GM containing MGF (10 ng/ml), dark grey bars are cells treated with GM containing IGF-I (10 ng/ml), ﬁlled bars are cells
treated with GM and MGF (10 ng/ml) and IGF-I (10 ng/ml). Signiﬁcance values: *P < 0.05, **P < 0.001, ***P < 0.0001.
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Cells were plated at 1000 cells per well and grown for 24 h on 96-well
plates before addition of IGF-I or MGF for 48 h. 5-Bromo-20-deoxy-
uridine (BrdU) was added to the cultures for the ﬁnal 5 h of the time
period as per the BrdU labelling and detection kit (Roche Applied Sci-
ences, UK). Cells were then ﬁxed, cellular DNA partially digested
through nuclease treatment, and incorporated BrdU detected and
quantiﬁed by a peroxidase-labelled antibody to BrdU. The peroxidase
catalyzes the cleavage of the substrate in a colour reaction. The absor-
bance at 390 nm is directly correlated to the level of BrdU incorpora-
tion and this signal was measured using a Tecan microplate reader.
Each data point represents the mean of four separate wells run in
two experiments.
2.5. Creatine phosphokinase (CPK) assay
This assay was performed using previously published protocols [11].
Measurement of CPK allows for the quantitative comparison of myo-
genesis and it is a marker of myotube formation. CPK activity was
measured using the colorimetric method based on the generation of
inorganic phosphate. This was then expressed in terms of the protein
content of the culture. Previously expanded primary human muscle cellcultures were re-plated at 10 · 104 cells/well in 0.2% gelatin coated 96
well plates. Cells were cultured until 70/80% conﬂuent in GM then
the medium changed to diﬀerentiation medium (DM; DMEM, 2%
FCS, penicillin (100 U/ml) and streptomycin (100 lg/ml)) containing
the 24 aa MGF E domain peptide synthesized as previously described
[15] and/or human 70 aa IGF-I peptide (Sigma–Aldrich IGF-I ER2).
After 48 h, cells were washed twice with ice-cold PBS and then stored
frozen in 0.5 mM glycine buﬀer (pH 6.75) at 70 C. Fixed cells were
lysed by rapid thawing and CPK assay kit used according to manufac-
turer’s instructions (Sigma–Aldrich). The protein concentration of
each sample was determined against an albumin standard curve using
the Pierce Micro BCA Kit (PerBio Science, UK Ltd., Northumber-
land, UK).
2.6. Statistical analysis
One-way ANOVA test was applied using StatView 4.51 (SAS Insti-
tute Inc., Cherwell Scientiﬁc Publishing Ltd, Oxford, UK) followed by
the Fisher’s PLSD post hoc test. P < 0.05 was considered signiﬁcant.
Data were pooled for all runs (minimum of 6) for all observations
on each condition including the two types of healthy muscle and pre-
sented as means ± S.D.
Fig. 3. MGF increases the myogenic fraction but not via the IGF-I
receptor signalling pathway. (A) Myogenic cells that have diﬀerenti-
ated into myotubes under the inﬂuence of IGF-I (10 ng/ml) (C) and the
eﬀect of an anti-IGF-I receptor-blocking antibody (Ab-1; 100 lg/ml)
on that response (C+Ab-1). (B) Myogenic fraction of normal
craniofacial (N), CMD and ALS primary muscle cells treated with
growth medium (GM) alone (empty bars), GM and an anti-IGF-I
receptor blocking antibody (Ab-1; 100 lg/ml) (light grey bars), GM
and MGF (10 ng/ml) (dark grey bars), GM and MGF (10 ng/ml) and
an anti-IGF-I receptor-blocking antibody (Ab-1; 100 lg/ml) (ﬁlled
bars). Data shown are the means ±;S.D. pooled. Signiﬁcance values:
*P < 0.05, **P < 0.001, ***P < 0.0001.
2730 K. Ates et al. / FEBS Letters 581 (2007) 2727–27323. Results
Explant cultures were established and grown successfully
from all of the diﬀerent muscle groups used. The proportion
of myogenic precursors (desmin positive cells) in the total
mononuclear cell population was easily identiﬁed following
immunostaining (Fig. 1). As can be seen in Fig. 2A, MGF en-
riched the population of desmin positive (myogenic progeni-
tor) cells in normal muscle primary cultures after 48 h
incubation. In normal craniofacial (masseter) muscle the in-
crease was from 49.8 ± 2.4 to 68.8 ± 3.9 (% desmin positive
cells; P < 0.0001). In normal lower limb (quadriceps) muscle,
the MGF E domain increased the muscle progenitor cell pool
very signiﬁcantly (from 38.4 ± 2.5 to 57.9 ± 3.2% desmin posi-
tive cells; P < 0.0001). However, when IGF-I was combined
with MGF, it abrogated the MGF increase in desmin express-
ing cells. In order to conﬁrm that the MGF induced increase in
myogenic progenitors was due to proliferation of those cells
rather than conversion of non-myogenic to myogenic cells, a
commercially available cell source was treated with MGF or
IGF-I. Fig. 2B shows that proliferation (measured by BrdU as-
say) of a ‘‘pure’’ myogenic population was signiﬁcantly in-
creased (P < 0.05) with the MGF E domain but that IGF-I
had no eﬀect. It has been suggested that the muscle stem (satel-
lite) cells become exhausted in muscle wasting conditions by
repeated attempts at muscle cell repair. Fig. 2A shows that
although, the initial yield of desmin positive cells was less,
the MGF E domain did, however, signiﬁcantly increase the
putative muscle progenitor cell pool in dystrophic muscle with
CMD showing a signiﬁcant increase from 10.4 ± 17 to
17.5 ± 1.6 (% desmin positive cells, P < 0.0001) with similar re-
sults for FSH dystrophy from 11.7 ± 1.6 to 20.4 ± 2.1 (% des-
min positive cells; P = 0.0001) The same eﬀect of MGF on the
muscle progenitor cell pool was also seen after 48 h when using
cells from patients with ALS (4.8 ± 1.1 to 7.8 ± 0.8% desmin
positive cells; P = 0.0002). When combining both peptides
(Fig. 2) the inhibiting eﬀect of IGF-I was again observed as
for normal muscle. The increase in the numbers of desmin po-
sitive cells induced by MGF was reduced from 17.5 ± 1.6 to
13.1 ± 1.2 in CMD (P > 0.0001); 20.4 ± 2.1 to 14.5 ± 1.4 in
FSHD (P > 0.0001) and from 7.2 ± 0.1 to 5.3 ± 1.0
(P > 0.0024). Thus our data suggest that the MGF E domain
activates the muscle progenitor cells initially expressing des-
min. However, under the inﬂuence of IGF-I they enter the fu-
sion pathway and become removed from the stem cell pool.
To investigate if the enrichment of the human muscle pro-
genitor cell pool by the MGF E domain involves the IGF-I
receptor, a speciﬁc antibody was used to block this receptor.
Initially, the eﬃcacy of this antibody to block the IGF-I recep-
tor in our system was tested using our standard myogenic as-
say. IGF-I at a dose of 10 ng/ml induces myotube formation
(Fig. 3A; left panel) and this eﬀect can be completely blocked
when the anti-IGF-IR antibody Ab-1 is added with IGF-I
(Fig. 3A; right panel). As can be seen in Fig. 3B, in normal
muscle the enrichment of desmin positive cells induced by
MGF was not inhibited by the presence of the anti-IGFIR
antibody (68.8 ± 3.9 in MGF treated and 71.1 ± 6.2% desmin
positive cells in MGF plus Ab-1 treated cells; P = 0.2472).
The same eﬀect was also observed for both CMD and ALS
muscle (17.5 ± 1.6% vs. 16.7 ± 1.8% desmin positive cells,
P = 0.4589 for CMD; 7.2 ± 0.8% vs. 6.5 ± 0.8% desmin posi-
tive cells, P = 0.2933 for ALS). This indicates that the actionof the MGF E domain on the enrichment of the muscle pro-
genitor cell pool does not involve the IGF-I receptor and acts
as a separate growth/repair factor with a unique signalling
pathway.
The eﬀects of MGF E domain on preventing terminal diﬀer-
entiation are of considerable interest as this is a prerequisite for
replenishing the pool of muscle stem cells. The data in Fig. 4
show that expression of creatine phosphokinase (CPK), which
is a speciﬁc marker of diﬀerentiated muscle, is not induced by
MGF E domain. In contrast, IGF-I induced myogenic diﬀer-
entiation at a concentration of 10 ng/ml (as previously shown
in Fig. 3A). This was the same concentration at which the
numbers of cells expressing desmin was decreased, suggesting
recruitment of these cells into the myogenic pathway. In the
presence of 10 ng/ml IGF-I, MGF acted as an antagonist,
and suppressed diﬀerentiation to the myoblast fusion-compe-
tent stage in a dose dependent manner.4. Discussion
In healthy adult undamaged muscle, the satellite cells are
quiescent and situated between the basal lamina and the plas-
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Fig. 4. The eﬀect of IGF isoforms on myogenic diﬀerentiation of
normal craniofacial mononucleated cells into myotubes that express
creatine phosphokinase. Numbers refer to the dose of MGF or IGF in
ng/ml. Data shown are the means ± S.D. pooled. Signiﬁcance values:
*P < 0.05, **P < 0.001, ***P < 0.0001.
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cell. When activated they initiate Notch signalling [16,17],
co-express a number of markers including speciﬁc purinocep-
tors [18] M-Cadherin [2] and desmin [6], and then go on to be-
come intermediate progenitors and fusion competent
myoblasts. The upregulation of these markers is consequential
on the expression of MGF but not IGF-I Ea (shown in this
investigation for desmin) and it is likely that the MGF-induced
enrichment of the muscle precursor (desmin positive) pool we
see is due to expansion of already committed precursors; how-
ever, we cannot rule out the possibility that there is some con-
version of cells to the myogenic lineage from cells not
committed to that lineage. It makes biological sense for muscle
stem cells to be activated by MGF, which is expressed for a
short time after a mechanical challenge such as high resistance
exercise [5], rather than IGF-I Ea as this protein is the main
continuous source of mature IGF-I. Once myogenic precursor
cells have become activated to fusion-competent progenitors,
they must migrate successfully to form myotubes. Work pub-
lished whilst this manuscript was in preparation is of great
interest in this regard: Mills et al. have shown that MGF in-
creases myoblast migration [9]. In the current work, an inter-
esting ﬁnding was that although the ratio of muscle
progenitor (desmin positive) cells to total cells from patients
with CMD, FSHD and ALS is low compared to that in
healthy individuals, these cells increased in number when
MGF was provided. Thus it is debatable whether muscles in
these disease states degenerate because of lack of satellite cells
[19] or because of the inability to express this factor in ade-
quate amounts to continually replenish the stem cell pool.
The latter seems to be the most likely explanation, as we have
demonstrated that elderly people are unable to express MGF
at the levels required to maintain muscle, with similar ﬁndings
for FSHD and ALS patients (unpublished ﬁndings). Muscle
wasting is the main causes of death in patients with certain
neuromuscular diseases. Muscle loss can be linked to the
inability to express MGF [5], and to the fact that muscles ofthe mdx dystrophic mouse, a model for human Duchenne
Muscular Dystrophy, are unable to produce MGF even after
mechanical stimulation [20]. De Bari et al. [21] found that
when mesenchymal stem cells were introduced into dystrophic
muscles of mdx mouse, the sarcolemmal expression of dystro-
phin and also MGF expression was restored. Therefore, the
production of MGF may depend on the compliance of the cell
membrane and possibly involve some type of mechanotrans-
duction mechanism. Recent experiments have shown that
introduction of MGF as a plasmid construct markedly in-
creases muscle strength in mdx and normal mice and therefore
the prospects look promising for its use as a therapeutic agent
for loss of muscle strength in several medical conditions.Acknowledgments: The study was carried out with ﬁnancial support
from the Medical Research Council (MRC), the Wellcome Trust,
World Antidoping Association (WADA) and the Motor Neurone Dis-
ease Association of the UK.References
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